Posttranscriptional Stabilization Underlies p53-independent Induction of p21WAF1/CIP1/SDI1 in Differentiating Human Leukemic Cells

Journal of Clinical Investigation

Volumn 95, Issue 3, 1995, Pages 973-979

  Schwaller, J ^a   Koeffler, H P ^b   Niklaus, G ^a   Loetscher, P ^a   Nagel, S ^a   Fey, M F ^a   Tobler, A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immediate early gene; Leukemia; Myeloid differentiation; p21WAF1 CIP1 SDI1; Posttranscriptional stabilization

Indexed keywords

ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; ENZYME ACTIVITY; GENE DELETION; GENE INDUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RECEPTOR UPREGULATION; TRANSCRIPTION REGULATION;

COMPARATIVE STUDY; CYCLINS; DIMETHYL SULFOXIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTES; HUMAN; LEUKEMIA; MONOCYTES; PROTEIN P53; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION, GENETIC; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0028939009     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI117806     Document Type: Article

References (47)

1. Vogelstein, B., and K. W. Kinzler. 1992. p53 function and dysfunction. Cell. 70:523-526.
2. Kuerbitz, S. J., B. S. Plunkett, W. V. Walsh, and M. B. Kastan. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA. 89:7491-7495.
3. Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311.
4. Zambetti, G. P., and A. J. Levine. 1993. A comparison of the biological activities of wild-type and mutant p53. FASEB (Fed. Am. Soc. Exp. Biol.) J. 7:855-865.
5. Ginsberg, D., F. Mechtor, M. Yaniv, and M. Oren. 1991. Wild-type p53 can down-modulate the activity of various promotors. Proc. Natl. Acad. Sci. USA. 88:9979-9983.
6. Kastan, M. B., Q. Zhan, W. S. El-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. Fornace, Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-teleangiectasia. Cell. 71:587-597.
7. Barak, Y., T. Juven, R. Hafner, and M. Oren. 1993. MDM2 expression is induced by wild type p53 activity. EMBO (Eur. Mol. Biol. Organ.) J. 12:461-468.
8. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:817-825.
9. Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:805-816.
10. Xiong, Y., H. Zhang, and D. Beach. 1992. D-type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell. 71:505-514.
11. Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.). 366:701-704.
12. Xiong, Y., H. Zhang, and D. Beach. 1993. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes & Dev. 7:1572-1583.
13. Serrano, M., G. J. Hannon, and D. Beach. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.). 366:704-707.
14. Waga, S., G. J. Hannon, D. Beach, and B. Stillman. 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (Lond.). 369:574-578.
15. Noda, A., Y. Ning, S. F. Venable, O. M. Pereira-Smith, and J. R. Smith. 1994. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 211:90-98.
16. 1 arrest and apoptosis. Cancer Res. 54:1169-1174.
17. Dulic, V., W. K. Kaufmann, S. J. Wilson, T. D. Tisty, E. Lees, J. W. Harper, S. J. Elledge, and S. I. Reed. 1994. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 76:1013-1023.
18. Koeffler, H. P., C. Miller, M. A. Nicolson, J. Ranyard, and R. A. Bosselman. 1986. Increased expression of p53 protein in human leukemia cells. Proc. Natl. Acad. Sci. USA. 83:4035-4039.
19. Prokocimer, M., M. Shaklai, H. B. Bassat, D. Wolf, N. Goldfinger, and V. Rotter. 1986. Expression of p53 in human leukemia and lymphoma. Blood. 68:113-118.
20. Sugimoto, K., H. Toyoshima, R. Sakai, K. Miyagawa, K. Hagiwara, F. Ishikawa, F. Takaku, Y. Yazaki, and H. Hirai. 1992. Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood. 79:2378-2383.
21. Cheng, J., and M. Haas. 1990. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol. Cell. Biol. 10:5502-5509.
22. Gaidano, G., P. Ballerini, J. Z. Gong, G. Inghirami, A. Neri, E. W. Newcomb, I. T. Magrath, D. M. Knowles, and R. Dalla-Favera. 1991. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA. 88:5413-5417.
23. Hood-Edwards, R., and N. Raab-Traub. 1994. Alterations of the p53 gene in Epstein-Barr virus associated immunodeficiency-related lymphomas. J. Virol. 68:1309-1315.
24. Feinstein, E., G. Cimino, R. P. Gale, G. Alimena, R. Berthier, K. Kishi, J. Goldman, A. Zaccaria, A. Berrebi, and E. Canaani. 1991. p53 in chronic myelogenous leukemia in acute phase. Proc. Natl. Acad. Sci. USA. 88:6293-6297.
25. Bi, S., T. Hughes, J. Bungey, A. Chase, P. de Fabritiis, and J. M. Goldman. 1992. p53 in chronic myeloid leukemia cell lines. Leukemia (Baltimore). 6:839-842.
26. Wolf, D., and V. Rotter. 1985. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc. Natl. Acad. Sci. USA. 82:790-794.
27. Miller, C. W., K. Simon, A. Aslo, K. Kok, J. Yokota, C. H. Buys, M. Terada, and H. P. Koeffler. 1992. p53 mutations in human lung tumors. Cancer Res. 52:1695-1698.
28. Johnson, K. R., W. M. Nauseef, A. Care, M. J. Wheelock, S. Shane, S. Hudson, H. P. Koeffler, M. Selsted, C. Miller, and G. Rovera. 1987. Characterization of cDNA clones for human myeloperoxidase: predicted amino acid sequence and evidence for multiple mRNA species. Nucleic Acids Res. 15:2013-2019.
29. Lindley, I., H. Aschauer, J. M. Seifert, C. Lam, W. Brunowsky, E. Kowanzki, M. Thelen, P. Peveri, B. Dewald, V. von Tscharner, et al. 1988. Synthesis and expression in Escherichia coli of the gene encoding monocyte-derived neutrophil-activating factor. Proc. Natl. Acad. Sci. USA. 85:9199-9203.
30. Greenberg, M. E. 1988. Identification of newly transcribed RNA. In Current Protocols in Molecular Biology. F. M. Ausubel, editor. John Wiley & Sons, New York. 4.10.1-4.10.8.
31. Sen, S., R. Takahashi, S. Rani, E. Freireich, and S. Stass. 1993. Expression of differentially phosphorylated Rb and mutant p53 proteins in myeloid leukemia cell lines. Leuk. Res. 17:639-647.
32. Neubauer, A., M. He, C. A. Schmidt, D. Huhn, and E. T. Liu. 1993. Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques. Leukemia (Baltimore). 7:593-600.
33. Collins, S. J. 1987. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood. 70:1233-1244.
34. Meier, R. W., T. Chen, S. Matthews, G. Niklaus, and A. Tobler. 1992. The differentiation pathway of HL-60 cells is a model system for studying the specific regulation of some genes. Cell Growth & Differ. 3:663-669.
35. Kowalski, J., and D. T. Denhardt. 1989. Regulation of the mRNA for monocyte-derived neutrophil-activating peptide in differentiating HL60 promyelocytes. Mol. Cell. Biol. 9: 1946-1957.
36. Michieli, P., M. Chedid, D. Lin, J. H. Pierce, W. E. Mercer, and D. Givol. 1994. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 54:3391-3395.
37. Rovera, G., T. G. O'Brien, and L. Diamond. 1979. Induction of differentiation in human promyelocytic leukemia cells by tumor promotors. Science (Wash. DC). 204:868-870.
38. Koeffler, H. P., M. Bar-Eli, and M. C. Territo. 1981. Phorbol ester effect on differentiation of human myeloid leukemia cell lines blocked at different stages of maturation. Cancer Res. 41:919-926.
39. 1 arrest. J. Clin. Invest. 89:954-960.
40. Oda, T., K. Kitajima, T. Hirano, N. Shimizu, and H. Utiyama. 1993. Interplay between differentiation and cell cycle arrest at G1 in phorbol diestertreated human myelocytic leukemia cells. Int. J. Hematol. 58:125-128.
41. Yen, A., D. Brown, and J. Fishbaugh. 1987. Control of HL-60 monocytic differentiation. Exp. Cell Res. 168:247-254.
42. Yen, A. 1985. Control of HL-60 myeloid differentiation. Exp. Cell Res. 156:198-212.
43. Nishizuka, Y. 1988. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature (Lond.). 334:661-665.
44. Reichel, H., H. P. Koeffler, and A. Norman. 1989. The role of the vitamin D endocrine system in health and disease. N. Engl. J. Med. 320:980-991.
45. Herschmann, H. R. 1991. Primary response genes induced by growth factors and tumor promotors. Annu. Rev. Biochem. 60:281-319.
46. Schiavi, S. C., J. G. Belasco, and M. E. Greenberg. 1992. Regulation of proto-oncogene mRNA stability. Biochim. Biophys. Acta. 1114:95-106.
47. Mitchell, R., L. Zokas, R. Schreiber, and I. Verma. 1985. Rapid induction of the expression of proto-oncogene f os during human monocytic differentiation. Cell. 40:209-217.